• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Inspire Pharmaceuticals

edit

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development. The Company’s portfolio of products includes AzaSite, Elestat, Restasis, Denufosol tetrasodium, Prolacria, AzaSite and INS115644, INS117548.

Recent Milestones

edit

• 
  Inspire Pharmaceuticals was acquired by Merck & Co. for $430M. (4/5/11)
  Posted 4/5/11 at 11:06pm via merck.com
• 
  Inspire Pharmaceuticals added Robert M. Savel, II as Senior Vice President and CTO.
  Posted 9/6/10 at 7:09pm
• 
  Went public with stock symbol NASDAQ:ISPH.
  Posted 9/6/10 at 7:09pm
• 
  Inspire Pharmaceuticals added Adrian Adams as President & CEO.
  Posted 9/6/10 at 7:09pm

Videos

Screenshots

edit

Stock Price

Sources

1. Merck to Acquire Inspire Pharmaceuticals, Inc. (merck.com) [edit]